Glaukos share price logo

Glaukos

NYSE: GKOS

Large Cap

$181.91

+1.34

(+0.74%)

as on

Glaukos Stock Performance

as on August 28, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $178.43
    $183.31
    downward going graph

    1.91%

    Downside

    0.77%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $73.16
    $191.62
    downward going graph

    59.78%

    Downside

    5.34%

    Upside

    downward going graph

Glaukos share price movements today

Previous Close
$180.57
Open
$179.38
Volume
475.8K
Market Cap
$10.7B
Day's Low - High
$178.43 - $183.31
52 Week Low - High
$73.16 - $191.62

Glaukos Historical Returns

1 Month Return
+ 20.21 %
3 Month Return
+ 70.78 %
1 Year Return
+ 88.39 %
3 Year Return
+ 145.76 %
5 Year Return
+ 220.15 %

Glaukos Stock Fundamentals & Key Indicators

Check Glaukos market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$10.7B

EPS (TTM)

-3.25

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

18.96%

PE Ratio (TTM)

-55.81

Industry PE ratio

15.882666666666667

PEG Ratio

0.4960900993387595

EBITDA

-142.3M

Revenue (TTM)

612.8M

Profit Margin

79.12%

Return On Equity TTM

-27.07%

Glaukos Stock Valuation

Track how Glaukos P/E has moved over time to understand its valuation trends.

Glaukos in the last 5 years

  • Overview

  • Trends

Lowest (-54.13x)

December 31, 2024

Today (-34.42x)

December 31, 2025

Industry (15.88x)

December 31, 2025

Highest (-20.89x)

December 31, 2022

LowHigh

Today’s Price to Earnings Ratio: -34.42x

Glaukos vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Glaukos with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Glaukos image
Glaukos
BUY$10.7B220.15%-55.8179.12%NA
Edwards Lifesciences image
Edwards Lifesciences
BUY$52.3B-22.72%53.277.98%NA
Stryker image
Stryker
BUY$125.7B17.81%34.2314.43%105.3%
Medtronic image
Medtronic
BUY$116.7B-32.76%24.1565.02%3.15%
Abbott Laboratories image
Abbott Laboratories
BUY$201.9B-10.43%37.5311.65%213.54999999999998%
See all

Stock Returns calculator for Glaukos Stock including INR - Dollar returns

The Glaukos stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Glaukos investment value today

Current value as on today

₹2,05,302

Returns

₹1,05,302

(+105.3%)

Returns from Glaukos Stock

₹88,391 (+88.39%)

Dollar Impact

₹16,911 (+16.91%)

Analyst Recommendation on Glaukos Stock

Based on 13 analysts

BUY

92.31%

Buy

7.69%

Hold

0.00%

Sell

Based on 13 analysts, 92.3076923076923% of analysts recommend a 'BUY' rating for Glaukos. Average target price of $197.15

Glaukos Share Price Target

Get share price movements and forecasts by analysts on Glaukos.

What analysts predicted

7.73%UPSIDE

Target Price

$197.15

Current Price

$181.91

Analyzed by

13 Analysts

Target

$197.15

Glaukos target price $197.15, a slight upside of 7.73% compared to current price of $181.91. According to 13 analysts rating.

Indian Investors' Interest in Glaukos Stock

Search interest for Glaukos Stock has increased by 322% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:322% versus previous 30 day period

Glaukos Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
85
95
96
105
106
124
133
143
150
185
Gross Profit
65
73
74
76
82
97
104
111
117
151
Operating Income
-39
-29
-24
-28
-20
-22
-16
-27
-19
-17
EBITDA
-27
-36
-9
-22
-7
-8
-4
-125
-5
-6
Interest Expense
3
3
1
1
1
1
1
1
1
1
Depreciation
9
10
10
9
9
9
10
13
12
8
Income Before Tax
-40
-50
-21
-33
-17
-19
-15
-139
-19
-17
Income Tax Expense
0
0
0
0
0
0
0
-6
0
0
Net Income
-40
-50
-21
-33
-18
-19
-16
-133
-19
-18
Net Profit Margin
76.34%
76.43%
76.64%
72.86%
77.20%
78.33%
78.41%
77.80%
77.86%
81.67%

Glaukos Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
159
181
236
224
294
282
314
383
507
Gross Profit
138
156
198
133
227
213
239
289
393
Operating Income
-2
-13
-50
-123
-32
-82
-128
-122
-86
EBITDA
5
-6
-37
-83
-1
-48
-82
-95
-146
Interest Expense
-
-
2
14
13
13
13
10
4
Depreciation
5
6
9
34
34
35
37
39
42
Income Before Tax
0
-12
-50
-132
-49
-98
-133
-145
-193
Income Tax Expense
0
0
-65
-11
0
0
0
0
-5
Net Income
0
-12
15
-120
-49
-99
-134
-146
-187
Net Profit Margin
86.78%
86.17%
83.72%
59.23%
77.34%
75.61%
75.99%
75.48%
77.49%

Glaukos Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-40
-50
-21
-33
-18
-19
-16
-133
-19
-18
Operating Cash Flow
-33
-18
-9
0
-18
6
-10
6
-12
14
Investing Cash Flow
-29
34
30
11
-36
-20
-3
-15
10
-5
Financing Cash Flow
13
8
9
60
1
2
5
2
15
0
Change in Cash
-50
25
32
69
-55
-14
-2
-7
13
9

Glaukos Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
0
-12
15
-120
-49
-99
-134
-146
-133
Operating Cash Flow
25
18
0
-22
24
-33
-57
-61
-46
Investing Cash Flow
-11
-26
43
-205
-58
44
14
47
-77
Financing Cash Flow
4
21
-9
262
39
6
15
91
11
Change in Cash
18
14
32
34
4
18
-26
76
-111

Mutual Funds that own Glaukos Stock

Check out the Mutual Funds with significant holdings in Glaukos.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
7.443533%
4390489
JANUS INVESTMENT FUND
6.04293%
3564358
VANGUARD HORIZON FUNDS
2.880058%
1698772
PRIMECAP Odyssey Funds
2.486173%
1466443
SMALLCAP World Fund Inc
2.309786%
1362403
See all

Global Institutional Holdings in Glaukos

Funds
Holdings
iShares
11.62%
Vanguard
9.11%
Theofanis Kolokotrones
5.16%
SPDR
1.96%
Richard Driehaus
1.1%
See all

Glaukos News & Key Events

  • img

    Today's Timeline - 19 August

    Wed, 04:30 PM

    -

    Glaukos announces participation in Wells Fargo Healthcare Conference on September 9, 2026.

    Wed, 07:45 PM

    -

    Glaukos shows strong growth potential with increased sales and raised revenue guidance for 2026, despite some risks.

Insights on Glaukos

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 12 quarters, 78.04M → 185.61M (in $), with an average increase of 7.4% per quarter

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, GKOS has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 3 quarters, -133.65M → -18.37M (in $), with an average increase of 291.6% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, GKOS stock has moved up by 70.8%

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, GKOS has outperformed top 5 stocks with highest market-cap in its industry

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
OrganisationGlaukos
HeadquartersOne Glaukos Way, Aliso Viejo, CA, United States, 92656
IndustryMedical Devices
CEOMr. Thomas William Burns
E-voting on sharesClick here to vote

Key Management of Glaukos

Name

Title

Mr. Robert L. Davis J.D.

Senior VP, General Counsel & Business Development

Ms. Diana A. Scherer

VP of Compliance & Deputy General Counsel

Ms. Tracy M. Founds

Senior Vice President of Global Quality & Medical Safety

Mr. Alex R. Thurman

Senior VP & CFO

Dr. Tomas Navratil Ph.D.

Chief Development Officer

Mr. Christopher William Lewis

Vice President of Investor Relations & Corporate Affairs

Mr. L. Jay Katz FACS, M.D.

Chief Medical Officer

Mr. Thomas William Burns

Chairman & CEO

Mr. Joseph E. Gilliam

President & COO

Ms. Michele M. Allegretto

Senior Vice President of Human Resources

FAQs

What is Glaukos share price today?

Glaukos share price today is $181.91 as on at the close of the market. Glaukos share today touched a day high of $183.31 and a low of $178.43.

What is the 52 week high and 52 week low for Glaukos share?

Glaukos share touched a 52 week high of $191.62 on and a 52 week low of $73.16 on . Glaukos stock price today i.e. is closed at $181.91,which is 5.07% down from its 52 week high and 148.65% up from its 52 week low.

What is Glaukos's market capitalisation today?

Glaukos market capitalisation is $0.01T as on .

How to invest in Glaukos Stock (GKOS) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Glaukos on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Glaukos Shares that will get you 0.0082 shares as per Glaukos share price of $181.91 per share as on August 28, 2026 at 8:45 am IST.

What is the minimum amount required to buy Glaukos Stock (GKOS) from India?

Indian investors can start investing in Glaukos (GKOS) shares with as little as ₹95.53 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹955.30 in Glaukos stock (as per the Rupee-Dollar exchange rate as on ). Based on Glaukos share’s latest price of $181.91 as on August 28, 2026 at 8:45 am IST, you will get 0.0550 shares of Glaukos. Learn more about fractional shares .

What are the returns that Glaukos has given to Indian investors in the last 5 years?

Glaukos stock has given 220.15% share price returns and 30.32% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?